EU signs a deal with Gilead to provide COVID-19 medicine remdesivir

The European Union’s executive said it has signed a contract with Gilead for its COVID-19 medicine remdesivir that would cover 30,000 patients in the bloc from early August.

The contract was worth 63 million euros ($73.99 million) and would provide treatment to 30,000 patients with severe COVID-19 symptoms.

The first batch will address just immediate needs. At the same time, the Commission is also now preparing joint procurement for further supplies of this medicine, which will cover additional needs from October onward